Literature DB >> 23617697

Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.

Junjie Fu1, Ling Liu, Zhangjian Huang, Yisheng Lai, Hui Ji, Sixun Peng, Jide Tian, Yihua Zhang.   

Abstract

A series of hybrids from O(2)-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid (OA) were designed, synthesized, and biologically evaluated as novel nitric oxide (NO)-releasing prodrugs that could be activated by glutathione S-transferase π (GSTπ) overexpressed in a number of cancer cells. It was discovered that the most active compound, 21, released high levels of NO selectively in HCC cells but not in the normal cells and exhibited potent antiproliferative activity in vitro as well as remarkable tumor-retarding effects in vivo. Compared with the reported GSTπ-activated prodrugs JS-K and PABA/NO, 21 exhibited remarkably improved stability in the absence of GSTπ. Importantly, the decomposition of 21 occurred in the presence of GSTπ and was much more effective than in glutathione S-transferase α. Additionally, 21 induced apoptosis in HepG2 cells by arresting the cell cycle at the G2/M phase, activating both the mitochondrion-mediated pathway and the MAPK pathway and enhancing the intracellular production of ROS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23617697     DOI: 10.1021/jm400393u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

Review 1.  Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence.

Authors:  Muthu K Shanmugam; Xiaoyun Dai; Alan Prem Kumar; Benny K H Tan; Gautam Sethi; Anupam Bishayee
Journal:  Cancer Lett       Date:  2014-01-30       Impact factor: 8.679

Review 2.  Nitric oxide in liver diseases.

Authors:  Yasuko Iwakiri; Moon Young Kim
Journal:  Trends Pharmacol Sci       Date:  2015-05-28       Impact factor: 14.819

Review 3.  The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications.

Authors:  Kearsley M Dillon; Ryan J Carrazzone; John B Matson; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2020-03-26       Impact factor: 5.858

4.  Side chain-functionalized aniline-derived ursolic acid derivatives as multidrug resistance reversers that block the nuclear factor-kappa B (NF-κB) pathway and cell proliferation.

Authors:  Ri-Zhen Huang; Shi-Xian Hua; Zhi-Xin Liao; Xiao-Chao Huang; Heng-Shan Wang
Journal:  Medchemcomm       Date:  2017-05-12       Impact factor: 3.597

Review 5.  Glutathione S-conjugates as prodrugs to target drug-resistant tumors.

Authors:  Emma E Ramsay; Pierre J Dilda
Journal:  Front Pharmacol       Date:  2014-08-11       Impact factor: 5.810

6.  Synthesis, Biological Activity, and Apoptotic Properties of NO-Donor/Enmein-Type ent-Kauranoid Hybrids.

Authors:  Dahong Li; Xu Hu; Tong Han; Shengtao Xu; Tingting Zhou; Zhenzhong Wang; Keguang Cheng; Zhanlin Li; Huiming Hua; Wei Xiao; Jinyi Xu
Journal:  Int J Mol Sci       Date:  2016-05-24       Impact factor: 5.923

7.  Discovery of Farnesoid X Receptor Antagonists Based on a Library of Oleanolic Acid 3-O-Esters through Diverse Substituent Design and Molecular Docking Methods.

Authors:  Shao-Rong Wang; Tingting Xu; Kai Deng; Chi-Wai Wong; Jinsong Liu; Wei-Shuo Fang
Journal:  Molecules       Date:  2017-04-26       Impact factor: 4.411

Review 8.  Hypoxia-activated prodrugs and redox-responsive nanocarriers.

Authors:  Yun Zeng; Jingwen Ma; Yonghua Zhan; Xinyi Xu; Qi Zeng; Jimin Liang; Xueli Chen
Journal:  Int J Nanomedicine       Date:  2018-10-18

9.  Direct reaction of amides with nitric oxide to form diazeniumdiolates.

Authors:  Ryan J Holland; John R Klose; Jeffrey R Deschamps; Zhao Cao; Larry K Keefer; Joseph E Saavedra
Journal:  J Org Chem       Date:  2014-09-22       Impact factor: 4.354

10.  Combination of betulinic acid with diazen-1-ium-1,2-diolate nitric oxide moiety donating a novel anticancer candidate.

Authors:  Laiyin Zhang; Shuangxing Hou; Bo Li; Jianjian Pan; Liping Jiang; Guiying Zhou; Hong Gu; Caixing Zhao; Huiping Lu; Fenfen Ma
Journal:  Onco Targets Ther       Date:  2018-01-15       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.